retatrutide clinical trial phase retatrutide New 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Eli Lilly infiltrates anti-obesity market

Thornton K, and Gorenstein DG

Eli Lilly is running a direct head-to-head trial comparing the two drugs (NCT06662383, 800 patients)

63 Albiglutide was approved for marketing in the European Union in March 2014 and in the United States in April 2014

Operational Efficiency: The study demonstrates the successful implementation of PEC technology for liraglutide purification, showing that the method can effectively handle complex, modified peptides while maintaining product quality

THEREFORE, clinical trial designers, investors, and regulators need to aim for more #clinicallyrelevant treatment target #endpoints beyond large magnitude wt loss, and also develop various drug #doses for the diverse intended populations and their different needs over time on their #weightmanagement journey